Prophylactic vaccinations in chronic kidney disease: Current status

References

• Neovius M, Jacobson SH, Eriksson JK, Elinder CG, Hylander B. Mortality in chronic kidney disease and renal replacement therapy: a population-based cohort study. BMJ Open 2014; 4: e004251; PMID:24549162; http://dx.doi.org/10.1136/bmjopen-2013-004251
   PubMedGoogle Scholar
• Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R, et al. Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 2014; 383: 1831-43; PMID:24856028; http://dx.doi.org/10.1016/S0140-6736(14)60384-6
   PubMed Web of Science ®Google Scholar
• Kalia H, Fabrizi F, Martin P. Hepatitis B virus and renal transplantation. Transplant Rev (Orlando) 2011; 25: 102-9; PMID:21530218; http://dx.doi.org/10.1016/j.trre.2011.02.001
   PubMedGoogle Scholar
• Vermeiren AP, Hoebe CJ, Dukers-Muijrers NHJ. High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. Clin Virol 2013; 58: 262-4; http://dx.doi.org/10.1016/j.jcv.2013.07.003
   PubMed Web of Science ®Google Scholar
• Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 2010; 33: 492-503; PMID:21029960; http://dx.doi.org/10.1016/j.immuni.2010.10.002
   PubMed Web of Science ®Google Scholar
• Cruz LJ, Tacken PJ, Rueda F, Domingo JC, Albericio F, Figdor CG. Targeting nanoparticles to dendritic cells for immunotherapy. Methods Enzymol 2012; 509: 143-63; PMID:22568905; http://dx.doi.org/10.1016/B978-0-12-391858-1.00008-3
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients. Hepat Mon 2012; 12: e7359; PMID:23326280; http://dx.doi.org/10.5812/hepatmon.7359
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE. Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. Expert Rev Vaccines 2014; 13: 1317-26; PMID:25148051; http://dx.doi.org/10.1586/14760584.2014.944508
   PubMed Web of Science ®Google Scholar
• Mathew R, Mason D, Kennedy JS. Vaccination issues in patients with chronic kidney disease. Expert Rev Vaccines 2014; 13: 285-98; PMID:24405403; http://dx.doi.org/10.1586/14760584.2014.874950
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr 2012; 22: 149-56; PMID:22200433; http://dx.doi.org/10.1053/j.jrn.2011.10.020
   PubMed Web of Science ®Google Scholar
• Geara AS, Castellanos MR, Bassil C, Schuller-Levis G, Park E, Smith M, Goldman M, Elsayegh S. Effects of parathyroid hormone on immune function. See comment in PubMed Commons belowClin Dev Immunol 2010; 2010: pii: 418695
   Google Scholar
• Brigotti M, Carnicelli D, Arfilli V, Tamassia N, Borsetti F, Fabbri E, Tazzari PL, Ricci F, Pagliaro P, Spisni E, et al. Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils. See comment in PubMed Commons belowJ Immunol 2013; 191: 4748-58; PMID:24068665
   PubMedGoogle Scholar
• Gollapudi P, Yoon JW, Gollapudi S, Pahl MV, Vaziri ND. Leukocyte toll-like receptor expression in end-stage kidney disease. Am J Nephrol 2010; 31: 247-54; PMID:20090311; http://dx.doi.org/10.1159/000276764
   PubMed Web of Science ®Google Scholar
• Wang ZS, Xu DM, Guan GJ, Cui MY, Wei Y, Tang LJ, Jia XY, Li WB. [Clinical significance of toll-like receptor 4 expression on the surface of peripheral blood mononuclear cells in uremic patients]. [Article in Chinese] Zhonghua Yi Xue Za Zhi 2010; 90: 2389-91
   PubMedGoogle Scholar
• Yang M, Gan H, Shen Q, Tang W, Du X, Chen D. Proinflammatory CD14+CD16+ monocytes are associated with microinflammation in patients with type 2 diabetes mellitus and diabetic nephropathy uremia. Inflammation 2012; 35: 388-96; PMID:21847775; http://dx.doi.org/10.1007/s10753-011-9374-9
   PubMed Web of Science ®Google Scholar
• Vallés PG, Melechuck S, González A, Manucha W, Bocanegra V, Vallés R. Toll-like receptor 4 expression on circulating leucocytes in hemolytic uremic syndrome. Pediatr Nephrol 2012; 27: 407-15; http://dx.doi.org/10.1007/s00467-011-2014-7
   PubMed Web of Science ®Google Scholar
• Zhou ZX, Zhang J, Sun L. C7: a CpG oligodeoxynucleotide that induces protective immune response against megalocytivirus in Japanese flounder (Paralichthys olivaceus) via Toll-like receptor 9-mediated signaling pathway. Dev Comp Immunol 2014; 44: 124-32; PMID:24333437; http://dx.doi.org/10.1016/j.dci.2013.12.002
   PubMed Web of Science ®Google Scholar
• Chua BY, Johnson D, Tan A, Earnest-Silveira L, Sekiya T, Chin R, Torresi J, Jackson DC. Hepatitis C VLPs delivered to dendritic cells by a TLR2 targeting lipopeptide results in enhanced antibody and cell-mediated responses. PLoS One 2012; 7: e47492; PMID:23091628; http://dx.doi.org/10.1371/journal.pone.0047492
   PubMed Web of Science ®Google Scholar
• Kim KW, Chung BH, Jeon EJ, Kim BM, Choi BS, Park CW, Kim YS, Cho SG, Cho ML, Yang CW. B cell-associated immune profiles in patients with end-stage renal disease (ESRD). Exp Mol Med 2012; 44: 465-72; PMID:22617684; http://dx.doi.org/10.3858/emm.2012.44.8.053
   PubMed Web of Science ®Google Scholar
• Pahl MV, Gollapudi S, Sepassi L, Gollapudi P, Elahimehr R, Vaziri ND. Effect of end-stage renal disease on B-lymphocyte subpopulations, IL-7, BAFF and BAFF receptor expression. Nephrol Dial Transplant 2010; 25: 205-12; PMID:19684120; http://dx.doi.org/10.1093/ndt/gfp397
   PubMed Web of Science ®Google Scholar
• Zhou L, Sun L, Wu H, Zhang L, Chen M, Liu J, Zhong R. Oridonin ameliorates lupus-like symptoms of MRL(lpr/lpr) mice by inhibition of B-cell activating factor (BAFF). Eur J Pharmacol 2013; 715: 230-7; PMID:23712004; http://dx.doi.org/10.1016/j.ejphar.2013.05.016
   PubMed Web of Science ®Google Scholar
• Lin SY, Liu JH, Wang SM, Wang IK, Tsai CA, Liu YL, Lin HH, Chang CC, Huang CC. Association of response to hepatitis B vaccination and survival in dialysis patients. BMC Nephrol 2012; 13: 97; PMID:22935561; http://dx.doi.org/10.1186/1471-2369-13-97
   PubMed Web of Science ®Google Scholar
• Brown CM, Donlon S, O'Kelly P, Casey AM, Collier C, Conlon PJ, Walshe JJ. A prospective study of hepatitis B vaccination - a comparison of responders versus nonresponders. Ren Fail 2011; 33: 276-9; PMID:21401350; http://dx.doi.org/10.3109/0886022X.2011.559300
   PubMed Web of Science ®Google Scholar
• Al Saran K, Sabry A, Al Halawany Z, Ismail M. Factors affecting response to hepatitis B vaccine among hemodialysis patients in a large Saudi Hemodialysis Center. Saudi J Kidney Dis Transpl 2014; 25: 185-91; PMID:24434410; http://dx.doi.org/10.4103/1319-2442.124572
   PubMedGoogle Scholar
• Grzegorzewska AE, Wobszal P, Jagodziński PP. Interleukin-18 promoter polymorphism and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients. Kidney Blood Press Res. 2012; 35: 1-8; PMID:21832842; http://dx.doi.org/10.1159/000329932
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE, Wobszal PM, Mostowska A, Jagodziński PP. Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients. BMC Nephrol 2012; 13: 75; PMID:22863216; http://dx.doi.org/10.1186/1471-2369-13-75
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE, Wobszal PM, Sowińska A, Mostowska A, Jagodziński PP. Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection. Mol Biol Rep 2013; 40: 6899-911; PMID:24158609; http://dx.doi.org/10.1007/s11033-013-2809-7
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE, Pajzderski D, Sowińska A, Mostowska A, Jagodziński PP. IL4R and IL13 polymorphic variants and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to HBV vaccination or infection. Vaccine 2013; 31: 1766-70; PMID:23462527; http://dx.doi.org/10.1016/j.vaccine.2013.02.023
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE, Pajzderski D, Sowińska A, Jagodziński PP. Polymporphism of monocyte chemoattractant protein 1 (MCP1 –2518 A/G) and responsiveness to hepatitis B vaccination in hemodialysis patients. Pol Arch Med Wewn 2014; 124: 10-8; PMID:24382482
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE, Pajzderski D, Sowińska A, Jagodziński PP. Monocyte chemoattractant protein-1 gene (MCP-1-2518 A/G) polymorphism and serological markers of hepatitis B virus infection in hemodialysis patients. Med Sci Monit 2014; 20: 1101-16; PMID:24975639; http://dx.doi.org/10.12659/MSM.891009
   PubMed Web of Science ®Google Scholar
• Zitt E, Sprenger-Mähr H, Knoll F, Neyer U, Lhotta K. Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. Vaccine 2012; 30: 931-5; PMID:22142584; http://dx.doi.org/10.1016/j.vaccine.2011.11.086
   PubMed Web of Science ®Google Scholar
• Grzegorzewska AE, Jodłowska E, Mostowska A, Sowińska A, Jagodziński PP. Single nucleotide polymorphisms of vitamin D binding protein, vitamin D receptor and retinoid X receptor α genes and response to hepatitis B vaccination in renal replacement therapy patients. Expert Rev Vaccines 2014; 13: 1395-403; PMID:25245883; http://dx.doi.org/10.1586/14760584.2014.962521
   PubMed Web of Science ®Google Scholar
• Duranti E, Duranti D. Polymethylmethacrylate strengthens antibody response in hemodialysis patients not responding to hepatitis B vaccine: preliminary data. Minerva Med 2011; 102: 469-74; PMID:22193378
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1-150; http://dx.doi.org/10.1038/kisup.2012.73
   Web of Science ®Google Scholar
• Recommended Adult Immunization Schedule — United States – 2015. http://www.cdc.gov/vaccines/schedules/hcp/imz/adult-conditions.html. Accessed February 22, 2015)
   Google Scholar
• Ghadiani MH, Besharati S, Mousavinasab N, Jalalzadeh M. Response rates to HB vaccine in CKD stages 3–4 and hemodialysis patients. J Res Med Sci 2012; 17: 527-33; PMID:23626628
   PubMed Web of Science ®Google Scholar
• Roznovský L, Tvrdík J, Kabieszová L, Petrousová L, Orságová I, Hozáková L, Lochman I, Kloudová A, Valkovský I, Letocha P, et al. [Vaccination against hepatitis B in patients with chronic renal failure–twenty years follow-up]. [Article in Czech] Vnitr Lek 2011; 57: 808-14
   PubMedGoogle Scholar
• Sawyer MH, Hoerger TJ, Murphy TV, Schillie SF, Hu D, Spradling PR, Byrd KK, Xing J, Reilly ML, Tohme RA, Moorman A, Smith EA, Baack BN, Jiles RB, Klevens M, Ward JW, Kahn HS, Zhou F. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep 2011; 60: 1709-25; PMID:22189894
   PubMedGoogle Scholar
• US. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013; http://www.usrds.org/atlas.aspx
   Google Scholar
• Garçon N. Preclinical development of AS04. Methods Mol Biol 2010; 626: 15-27; http://dx.doi.org/10.1007/978-1-60761-585-9_2
   PubMedGoogle Scholar
• Polito P, Di Lullo L, Iannacci GR, Cecilia A, Galderisi C, Gorini A. [Seroconversion and immune response after anti-HBV vaccination in patients on chronic hemodialysis: comparison of two vaccines]. [Article in Italian] G Ital Nefrol 2011; 28: 525-30
   PubMedGoogle Scholar
• Hoebe CJ, Vermeiren AP, Dukers-Muijrers NH. Revaccination with Fendrix® or HBVaxPro® results in better response rates than does revaccination with three doses of Engerix-B® in previous non-responders. Vaccine 2012; 30: 6734-7; PMID:22981848; http://dx.doi.org/10.1016/j.vaccine.2012.08.074
   PubMed Web of Science ®Google Scholar
• Beran J, Hobzova L, Wertzova V, Kuriyakose S, Leyssen M, Surquin M, Houard S. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum Vaccin 2010; 6: 578-84; PMID:20523113; http://dx.doi.org/10.4161/hv.6.7.11883
   PubMed Web of Science ®Google Scholar
• Tielemans CL, Vlasak J, Kosa D, Billiouw JM, Verpooten GA, Mezei I, Ryba M, Peeters PC, Mat O, Jadoul MY, et al. Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials. Vaccine 2011; 29: 1159-66; PMID:21167859; http://dx.doi.org/10.1016/j.vaccine.2010.12.009
   PubMed Web of Science ®Google Scholar
• Surquin M, Tielemans CL, Kulcsár I, Ryba M, Vörös P, Mat O, Treille S, Dhaene M, Stolear JC, Kuriyakose SO, et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine. Kidney Int 2010; 77: 247-55; PMID:19940840; http://dx.doi.org/10.1038/ki.2009.454
   PubMed Web of Science ®Google Scholar
• Surquin M, Tielemans C, Nortier J, Jadoul M, Peeters P, Ryba M, Roznovsky L, Domán J, Barthelemy X, Crasta PD, et al. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency. Hum Vaccin 2011; 7: 913-8; PMID:21892006; http://dx.doi.org/10.4161/hv.7.9.16225
   PubMed Web of Science ®Google Scholar
• Heplisav approval status. http://www.drugs.com/history/heplisav.html. Accessed February 23, 2015
   Google Scholar
• Halperin SA, Ward B, Cooper C, Predy G, Diaz-Mitoma F, Dionne M, Embree J, McGeer A, Zickler P, Moltz KH, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age. Vaccine 2012; 30: 2556-63; PMID:22326642; http://dx.doi.org/10.1016/j.vaccine.2012.01.087
   PubMed Web of Science ®Google Scholar
• Halperin SA, McNeil S, Langley JM, Smith B, MacKinnon-Cameron D, McCall-Sani R, Heyward WL, Martin JT. Safety and immunogenicity of different two-dose regimens of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in healthy young adults. Vaccine 2012; 30: 5445-8; PMID:22704926; http://dx.doi.org/10.1016/j.vaccine.2012.05.074
   PubMed Web of Science ®Google Scholar
• Halperin SA, Ward BJ, Dionne M, Langley JM, McNeil SA, Smith B, Mackinnon-Cameron D, Heyward WL, Martin JT. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine. Hum Vaccin Immunother 2013; 9: 1438-44; PMID:23571179; http://dx.doi.org/10.4161/hv.24256
   PubMed Web of Science ®Google Scholar
• Sablan BP, Kim DJ, Barzaga NG, Chow WC, Cho M, Ahn SH, Hwang SG, Lee JH, Namini H, Heyward WL. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012; 30: 2689-96; PMID:22342916; http://dx.doi.org/10.1016/j.vaccine.2012.02.001
   PubMed Web of Science ®Google Scholar
• Heyward WL, Kyle M, Blumenau J, Davis M, Reisinger K, Kabongo ML, Bennett S, Janssen RS, Namini H, Martin JT. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40–70 years of age. Vaccine 2013; 31: 5300-5; PMID:23727002; http://dx.doi.org/10.1016/j.vaccine.2013.05.068
   PubMed Web of Science ®Google Scholar
• Janssen RS, Mangoo-Karim R, Pergola PE, Girndt M, Namini H, Rahman S, Bennett SR, Heyward WL, Martin JT. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. Vaccine 2013; 31: 5306-13; PMID:23727422; http://dx.doi.org/10.1016/j.vaccine.2013.05.067
   PubMed Web of Science ®Google Scholar
• Halperin SA, Ward BJ, Dionne M, Langley JM, McNeil SA, Smith B, Mackinnon-Cameron D, Heyward WL, Martin JT. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine. Hum Vaccin Immunother 2013; 9: 1438-44; PMID:23571179; http://dx.doi.org/10.4161/hv.24256
   PubMed Web of Science ®Google Scholar
• Kuan RK, Janssen R, Heyward W, Bennett S, Nordyke R. Cost-effectiveness of hepatitis B vaccination using HEPLISAV™ in selected adult populations compared to Engerix-B® vaccine. Vaccine 2013; 31: 4024-32; PMID:23707166; http://dx.doi.org/10.1016/j.vaccine.2013.05.014
   PubMed Web of Science ®Google Scholar
• Di Pasquale A, De Ridder M, Van Der Meeren O. Hepatitis B virus vaccine in chronic kidney diseases: improved immunogenicity by adjuvants? Limits of a meta-analysis. Vaccine 2012; 30: 5586; PMID:22749597; http://dx.doi.org/10.1016/j.vaccine.2012.06.023
   PubMed Web of Science ®Google Scholar
• Saade F, Honda-Okubo Y, Trec S, Petrovsky N. A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine 2013; 31: 1999-2007; PMID:23306367; http://dx.doi.org/10.1016/j.vaccine.2012.12.077
   PubMed Web of Science ®Google Scholar
• Fakharzadeh S, Kalanaky S, Hafizi M, Goya MM, Masoumi Z, Namaki S, Shakeri N, Abbasi M, Mahdavi M, Nazaran MH. The new nano-complex, Hep-c, improves the immunogenicity of the hepatitis B vaccine. Vaccine 2013; 31: 2591-7; PMID:23583463; http://dx.doi.org/10.1016/j.vaccine.2013.03.030
   PubMed Web of Science ®Google Scholar
• Gray PM, Forrest G, Wisniewski T, Porter G, Freed DC, DeMartino JA, Zaller DM, Guo Z, Leone J, Fu TM, et al. Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol 2012; 278: 113-9; PMID:23121983; http://dx.doi.org/10.1016/j.cellimm.2012.07.006
   PubMed Web of Science ®Google Scholar
• Chen X, Zhang W, Gao W, Zou Q, Feng C, Liu H, Zhou C, Zhang Y, Wang B. Hemokinin-1 as an adjuvant molecule enhancing humoral and memory responses to HBsAg DNA vaccination. Viral Immunol 2012; 25: 289-96; PMID:22876773; http://dx.doi.org/10.1089/vim.2012.0015
   PubMed Web of Science ®Google Scholar
• Sanadgol H. Levamisole usage as an adjuvant to hepatitis B vaccine in hemodialysis patients, yes or no? Nephrourol Mon 2013; 5: 673-8; PMID:23577329; http://dx.doi.org/10.5812/numonthly.3985
   PubMedGoogle Scholar
• Afsharian M, Vaziri S, Janbakhsh AR, Sayad B, Mansouri F, Nourbakhsh J, Qadiri K, Najafi F, Shirvanii M. The effect of zinc sulfate on immunologic response to recombinant hepatitis B vaccine in elderly: Zinc sulfate and immunologic response to recombinant hepatitis B vaccine. Hepat Mon 2011; 11: 32-5; PMID:22087114
   PubMed Web of Science ®Google Scholar
• Janbakhsh A, Mansouri F, Vaziri S, Sayad B, Afsharian M, Rahimi M, Shahebrahimi K, Salari F. Effect of selenium on immune response against hepatitis B vaccine with accelerated method in insulin-dependent diabetes mellitus patients. Caspian J Intern Med 2013; 4: 603-6; PMID:24009944
   PubMedGoogle Scholar
• Mbaeyi C, Thompson ND. Hepatitis C Virus Screening and Management of Seroconversions in Hemodialysis Facilities. Seminar Dial 2013; 26: 439-46; http://dx.doi.org/10.1111/sdi.12097
   PubMed Web of Science ®Google Scholar
• Fauvelle C, Lepiller Q, Felmlee DJ, Fofana I, Habersetzer F, Stoll-Keller F, Baumert TF, Fafi-Kremer S. Hepatitis C virus vaccines - progress and perspectives. Microb Pathog 2013; 58: 66-72; PMID:23499591; http://dx.doi.org/10.1016/j.micpath.2013.02.005
   PubMed Web of Science ®Google Scholar
• Tung J, Carlisle E, Smieja M, Kim PT, Lee CH. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. Am J Kidney Dis 2010; 56: 713-9; PMID:20630640; http://dx.doi.org/10.1053/j.ajkd.2010.04.015
   PubMed Web of Science ®Google Scholar
• Beaumont E, Patient R, Hourioux C, Dimier-Poisson I, Roingeard P. Chimeric HBV-HCV envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine. Hepatology 2012; ; http://dx.doi.org/10.1002/hep.26132
   Web of Science ®Google Scholar
• Baker C, Pickering L, Chilton L, Cieslak P, Ehresmann K, Englund J, Judson F, Keitel W, Lett S, Marcy M, et al. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). National Center for Immunization and Respiratory Diseases. MMWR Recomm Rep 2011; 60: 1-64
   Google Scholar
• Wang IK, Lin CL, Lin PC, Liang CC, Liu YL, Chang CT, Yen TH, Morisky DE, Huang CC, Sung FC. Effectiveness of influenza vaccination in patients with end-stage renal disease receiving hemodialysis: a population-based study. PLoS One 2013; 8: e58317
   PubMed Web of Science ®Google Scholar
• McGrath LJ, Cole SR, Kshirsagar AV, Weber DJ, Stürmer T, Brookhart MA. Hospitalization and skilled nursing care are predictors of influenza vaccination among patients on hemodialysis: evidence of confounding by frailty. Med Care 2013; 51: 1106-13; PMID:23969584; http://dx.doi.org/10.1097/MLR.0b013e3182a50297
   PubMed Web of Science ®Google Scholar
• Wilmore SM, Philip KE, Cambiano V, Bretherton CP, Harborne JE, Sharma A, Jayasena SD. Influenza and pneumococcal vaccinations in dialysis patients in a London district general hospital. Clin Kidney J 2014; 7: 27-32; PMID:24466425; http://dx.doi.org/10.1093/ckj/sft138
   PubMedGoogle Scholar
• Kumar D, Morris MI, Kotton CN, Fischer SA, Michaels MG, Allen U, Blumberg EA, Green M, Humar A, Ison MG. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10: 18-25; PMID:19958321; http://dx.doi.org/10.1111/j.1600-6143.2009.02960.x
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29: 2461-73; PMID:21256188; http://dx.doi.org/10.1016/j.vaccine.2011.01.011
   PubMed Web of Science ®Google Scholar
• Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, et al. Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A phase III, placebo-controlled, randomized study. J Infect Dis 2011; 203: 1729-38; PMID:21606531; http://dx.doi.org/10.1093/infdis/jir172
   PubMed Web of Science ®Google Scholar
• Broeders NE, Hombrouck A, Lemy A, Wissing KM, Racapé J, Gastaldello K, Massart A, Van Gucht S, Weichselbaum L, De Mul A, et al. Influenza A/H1N1 vaccine in patients treated by kidney transplant or dialysis: a cohort study. Clin J Am Soc Nephrol 2011; 6: 2573-8; PMID:21921153; http://dx.doi.org/10.2215/CJN.04670511
   PubMed Web of Science ®Google Scholar
• Labriola L, Hombrouck A, Marechal C, Van GS, Brochier B, Thomas I, Jadoul M, Goubau P. Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. Nephrol Dial Transplant 2011; 26: 1424-28; PMID:21273236; http://dx.doi.org/10.1093/ndt/gfq782
   PubMed Web of Science ®Google Scholar
• Brakemeier S, Schweiger B, Lachmann N, Glander P, Schonemann C, Diekmann F, Neumayer HH, Budde K. Immune response to an adjuvanted influenza A H1N1 vaccine (Pandemrix®) in renal transplant recipients. Nephrol Dial Transplant 2012; 27: 423-8; PMID:21613386; http://dx.doi.org/10.1093/ndt/gfr278
   PubMed Web of Science ®Google Scholar
• Dikow R, Eckerle I, Ksoll-Rudek D, Hampel H, Schwenger V, Zeier M, Schnitzler P, Sommerer C. Immunogenicity and Efficacy in Hemodialysis Patients of an AS03A-Adjuvanted Vaccine for 2009 Pandemic Influenza A(H1N1): A Nonrandomized Trial. Am J Kidney Dis 2011; 57: 716-23; PMID:21349617
   PubMed Web of Science ®Google Scholar
• Esposito S, Mastrolia MV, Ghio L, Paglialonga F, Terranova L, Scala A, Edefonti A, Principi N. Influenza immunization in hemodialyzed or kidney transplanted adolescents and young adults. Expert Rev Vaccines 2014; 13: 1059-66; PMID:24972949
   PubMed Web of Science ®Google Scholar
• Azak A, Huddam B, Kocak G, Altas AB, Duranay M, Korukluoglu G. Antibody response after single H1N1 influenza vaccine in chronic dialysis patients. Ther Apher Dial 2013; 17: 55-9; PMID:23379494
   PubMed Web of Science ®Google Scholar
• Quintana LF, Serra N, De Molina-Llauradó P, Blasco M, Martinez M, Campos B, Bayas JM, Pumarola T, Campistol JM. Influence of renal replacement therapy on immune response after one and two doses of the A(H1N1) pdm09 vaccine. Influenza Other Respir Viruses 2013; 7: 809-14; PMID:23078139
   PubMed Web of Science ®Google Scholar
• Moon SJ, Lee SH, Byun YH, Yun GY, Kim SK, Seong BL, Kim AR, Sun Park E, Kim HJ, Lee JE, et al. Risk factors affecting seroconversion after influenza A/H1N1 vaccination in hemodialysis patients. BMC Nephrol 2012; 13: 165; PMID:23206898
   PubMed Web of Science ®Google Scholar
• Bond TC, Spaulding AC, Krisher J, McClellan W. Mortality of dialysis patients according to influenza and pneumococcal vaccination status. Am J Kidney Dis 2012; 60: 959-65; PMID:22694948
   PubMed Web of Science ®Google Scholar
• Duggal T, Segal P, Shah M, Carter-Monroe N, Manoharan P, Geetha D. Antineutrophil cytoplasmic antibody vasculitis associated with influenza vaccination. Am J Nephrol 2013; 38: 174-8; PMID:23941822
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012; 61: 816-9; PMID:23051612; http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6140a4.htm
   PubMedGoogle Scholar
• Gilbertson DT, Guo H, Arneson TJ, Collins AJ. The association of pneumococcal vaccination with hospitalization and mortality in hemodialysis patients. Nephrol Dial Transplant 2011; 26: 2934-9; PMID:21317410
   PubMed Web of Science ®Google Scholar
• Bitsaktsis C, Iglesias BV, Li Y, Colino J, Snapper CM, Hollingshead SK, Pham G, Gosselin DR, Gosselin EJ. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity. Infect Immun 2012; 80: 1166-80; PMID:22158740
   PubMed Web of Science ®Google Scholar